drugset / Trial / NCT07566897
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2029-12
- Completion
- 2030-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darleukin | Protein / enzyme biologic | — | Intravenous |
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |